Status:

TERMINATED

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

Lead Sponsor:

Momenta Pharmaceuticals, Inc.

Conditions:

Immune Thrombocytopenic Purpura (ITP)

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and i...

Detailed Description

The Part A of the study is currently not accepting healthy volunteers as the recruitment for the part A has completed.

Eligibility Criteria

Inclusion

  • Key Criteria for Healthy Volunteers: Subject must be between the ages of 18 and 55 years; healthy as indicated by medical history, physical examination, vital signs, clinical laboratory tests, and 12-lead electrocardiogram, and all abnormal findings are assessed as not clinically significant by the Investigator; not pregnant or breastfeeding; and no other clinically relevant abnormalities currently or in their history that the Investigator would deem them ineligible to participate.
  • Key Criteria for Immune Thrombocytopenic Purpura (ITP) Patients: Patient must be aged ≥18 years and diagnosed with ITP at least 3 months prior to screening, stable maintenance therapy for at least 4 weeks prior to the first study visit, not pregnant or breastfeeding, and no other clinically relevant abnormalities currently or in their history that the Investigator would deem them ineligible to participate.

Exclusion

    Key Trial Info

    Start Date :

    December 21 2018

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 9 2021

    Estimated Enrollment :

    50 Patients enrolled

    Trial Details

    Trial ID

    NCT03866577

    Start Date

    December 21 2018

    End Date

    June 9 2021

    Last Update

    May 28 2025

    Active Locations (28)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 7 (28 locations)

    1

    University of Southern California

    Los Angeles, California, United States, 90089

    2

    Oncology Institute of Hope and Innovation

    Whittier, California, United States, 90603

    3

    Lakes Research

    Miami Lakes, Florida, United States, 33014

    4

    University of South Florida

    St. Petersburg, Florida, United States, 33701